Bicycle Therapeutics Plc - ADR

NASDAQ:BCYC  
30.00
+0.48 (+1.63%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)717.00M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.29 Million
Adjusted EPS-$0.71
See more estimates
10-Day MA$29.82
50-Day MA$30.28
200-Day MA$23.94
See more pivots

Bicycle Therapeutics Plc - ADR Stock, NASDAQ:BCYC

Building 900, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT
Phone: +44.1223.261503
Number of Employees: 87

Description

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.